Incidence and Prognosis of COVID-19 in Patients with Psoriasis: A Multicenter Prospective Study from the Eastern Black Sea Region of Turkey.

COVID-19 infection can have a poor prognosis, especially in patients with chronic diseases and those receiving immunosuppressive or immunomodulating therapies. This study aimed to investigate the severity of COVID-19 infection in patients with psoriasis and compare the infection severity for systemic treatments and comorbidities. We conducted a study in the dermatology clinics of five different centers in the Eastern Black Sea region of Turkey. Four hundred and eighty-eight patients were included, and 22.5% were confirmed as having COVID-19 infection. In our study, the frequency of hospitalization rates due to COVID-19 infection were similar (15.4%, 25.9% respectively) in patients receiving biological treatment and receiving non-biological systemic treatment (P=0.344). Hospitalization rates were higher in patients with hypertension, androgenetic alopecia, and acitretin use (P=0.043, P=0.028, P=0.040). In conclusion, current biologic treatments and non-biologic systemic treatments in patients with psoriasis did not appear to increase the risk of the severe form of COVID-19, except for acitretin.

Is systemic isotretinoin use a risk factor for coronavirus disease 2019 (COVID-19)?

AIM: To investigate whether acne treatment agent systemic isotretinoin causes susceptibility to COVID-19 disease. MATERIAL AND METHOD: Patients admitted to a single center due to acne between March 2020 and December 2020 were included. A retrospective analysis was conducted on the medical records of acne patients receiving systemic isotretinoin or topical treatments. The patients with PCR-confirmed SARS-CoV-2 infection were recorded. RESULTS: 302 patients who used isotretinoin and 329 patients who used topical treatment were included in the study. No statistically significant difference was found between the groups in terms of age (p = 0.151). It was found that of the 302 patients who used isotretinoin, 33 had PCR test for SARS-CoV-2 and two of these had PCR positivity, while of the 329 patients who received topical treatment, 45 had PCR test and five of these had PCR positivity. No statistically significant difference was found between the groups in terms of having SARS-CoV-2 positivity with PCR (p = 0.692). CONCLUSION: Susceptibility to COVID-19 disease was not observed in patients using systemic isotretinoin.

Investigation of the relationship between alopecia areata and inflammatory blood parameters.

AIM: Alopecia areata (AA) is an inflammatory condition that causes regional shedding without scarring on the hair or eyebrows, eyelashes, and beard. In studies conducted, it has been concluded that platelet/lymphocyte ratio (PLR), neutrophil/lymphocyte ratio (NLR), and mean platelet volume (MPV) are significant indicators of systemic inflammation in various diseases. In the present study, our aim was to examine these parameters in AA patients and to investigate their relationship with the disease. MATERIALS AND METHODS: A total of 135 AA patients and 135 healthy controls who did not have any systemic, inflammatory, infectious, or autoimmune diseases were included in this study. Demographic characteristics and complete blood count (CBC) results were analyzed retrospectively and recorded, and statistical analysis was performed. RESULTS: PLR, NLR, and MPV values were not differ between AA patients and the control group. CONCLUSION: It can be concluded that PLR, NLR, and MPV values are not convenient parameters to show inflammatory response in AA.

Assessment of HLA-A, HLA-DR, and HLA-DQ alleles in patients with pemphigus vulgaris from eastern of Turkey.

BACKGROUND: Pemphigus vulgaris (PV) is a chronic progressive autoimmune bullous disease caused by the interaction of pathogenic factors, genetic, and environmental factors. HLA alleles, which are considered as protective factors against disease or predisposing factors, may be different in various populations and ethnic groups. AIMS: The purpose of this study is to examine the HLA-A, HLA-DR, and HLA-DQ alleles in patients that are diagnosed with PV in and around eastern of Turkey and to determine the alleles that create predisposition to disease or protect against the disease. PATIENTS/METHODS: Thirty patients diagnosed as PV with clinical, histopathological, and immunofluorescence findings and 30 healthy subjects were included in this study. The HLA-A, HLA-DR, and HLA-DQ typology in the DNA samples that were obtained from the blood samples of the groups was performed by using the PCR-SSP low-resolution gene panels. RESULTS: The HLA-A*03 allele was found to be significantly higher in patient group than the control group (P-value: .020). HLA-DRB1*04 and HLA-DRB1*14 alleles in PV patients were found to be significantly higher than the control group (P-value = .000). CONCLUSION: It was concluded that the HLA-DRB1*03, HLADQB1*02, and HLA-DQB1*06 alleles in and around eastern of Turkey showed protective effects against pemphigus vulgaris. It was also concluded that the HLA-A*03, HLA-DRB1*04, HLA-DRB1*14, HLA-DRB4, HLA-DQB1*03, and HLA-DQB1*05 alleles could cause predisposition to the disease.